Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07488377

Turkish Cognitive Self-Efficacy Questionnaire in Parkinson's Disease

This study aims to evaluate the validity and reliability of the Turkish version of the Cognitive Self-Efficacy Questionnaire in individuals with Parkinson's disease.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Parkinson Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinsonian Disorders Synucleinopathies

Age range

40 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Acibadem University

Istanbul, Turkey, +90, Turkey (Türkiye)

Location status: Recruiting

Location contact

Nuray ALACA

CONTACT

[email protected]

05324251290

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical diagnosis of Parkinson's disease
  • Hoehn and Yahr stage 1-3
  • Age 40 to 85 years
  • Mini-Mental State Examination (MMSE) score ≥24
  • Able to communicate and complete study assessments
  • Attending the Movement Disorders Outpatient Clinic, Department of Neurology, Istanbul Cerrahpaşa Faculty of Medicine Hospital
  • Able and willing to provide written informed consent

Exclusion criteria

  • Major depressive disorder or psychotic disorder
  • Advanced dementia
  • Severe visual impairment that may interfere with study assessments
  • Severe hearing impairment that may interfere with study assessments
  • Inability to cooperate with the physiotherapist
  • Inability to complete the study assessments

Treatment and study plan

Cognitive Self-Efficacy Questionnaire (Turkish Version)

Other

Participants will complete the Turkish version of the Cognitive Self-Efficacy Questionnaire to assess cognitive self-efficacy. The questionnaire will be administered for the evaluation of its validity and reliability in individuals with Parkinson's disease.

Primary outcomes

  1. Validity and Reliability of the Turkish Version of the Cognitive Self-Efficacy Questionnaire (CSEQ)

    Time frame: Baseline and 14-21 days for test-retest assessment

    Assessment of the psychometric properties of the Turkish version of the CSEQ in individuals with Parkinson's disease, including internal consistency (Cronbach's alpha), test-retest reliability (intraclass correlation coefficient), and construct validity through factor and correlation analyses.

Secondary outcomes

  1. Self-Efficacy for Managing Chronic Disease (6-Item Scale)

    Time frame: Baseline

    Assessment of perceived self-efficacy in managing chronic disease using the 6-Item Self-Efficacy for Managing Chronic Disease Scale. The scale evaluates individuals' confidence in managing symptoms such as pain, fatigue, emotional distress, and disease-related problems. It consists of 6 items scored on a 10-point Likert scale (1 = not at all confident, 10 = totally confident), with the total score calculated as the mean of all items. Higher scores indicate greater self-efficacy in disease management. The validated Turkish version will be used.

  2. Montreal Cognitive Assessment (MoCA-TR)

    Time frame: Baseline

    Cognitive function will be assessed using the Turkish version of the Montreal Cognitive Assessment (MoCA-TR). This screening tool evaluates multiple cognitive domains including visuospatial/executive functions, naming, attention, language, abstraction, delayed recall, and orientation. The total score ranges from 0 to 30, with higher scores indicating better cognitive function. The validated Turkish version for Parkinson's disease will be used.

Study contacts

Contact information is provided by the study sponsor or research team.

Nuray ALACA

CONTACT

[email protected]

05324251290

Sponsors and collaborators

Lead sponsor

Acibadem University

Other

Registry information

Official study title

Validity and Reliability of the Turkish Version of the Cognitive Self-Efficacy Questionnaire in Individuals With Parkinson's Disease

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Mar 23, 2026
Registry last updated
Jul 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.